Department of Bioengineering, Nanotechnology Research and Teaching Facility, [corrected] University of Texas at Arlington, Arlington, Texas 76019, USA.
Cancer Res. 2010 Nov 15;70(22):9371-80. doi: 10.1158/0008-5472.CAN-10-0568. Epub 2010 Nov 9.
Exposing rare but highly malignant tumor cells that migrate from the primary tumor mass into adjacent tissue(s) or circulate in the bloodstream is critical for early detection and effective intervention(s). Here, we report on an aptamer-based strategy directed against epidermal growth factor receptor (EGFR), the most common oncogene in glioblastoma (GBM), to detect these deadly tumor cells. GBMs are characterized by diffuse infiltration into normal brain regions, and the inability to detect GBM cells renders the disease surgically incurable with a median survival of just 14.2 months. To test the sensitivity and specificity of our platform, anti-EGFR RNA aptamers were immobilized on chemically modified glass surfaces. Cells tested included primary human GBM cells expressing high levels of the wild-type EGFR, as well as genetically engineered murine glioma cells overexpressing the most common EGFR mutant (EGFRvIII lacking exons 2-7) in Ink4a/Arf-deficient astrocytes. We found that surfaces functionalized with anti-EGFR aptamers could capture both the human and murine GBM cells with high sensitivity and specificity. Our findings show how novel aptamer substrates could be used to determine whether surgical resection margins are free of tumor cells, or more widely for detecting tumor cells circulating in peripheral blood to improve early detection and/or monitoring residual disease after treatment.
揭示从原发性肿瘤转移到邻近组织或循环到血液中的罕见但高度恶性的肿瘤细胞对于早期检测和有效干预至关重要。在这里,我们报告了一种针对表皮生长因子受体(EGFR)的适体策略,EGFR 是胶质母细胞瘤(GBM)中最常见的癌基因,用于检测这些致命的肿瘤细胞。GBM 的特征是弥漫性浸润到正常脑组织中,并且无法检测到 GBM 细胞,使得该疾病在手术上无法治愈,中位生存期仅为 14.2 个月。为了测试我们平台的灵敏度和特异性,将抗 EGFR RNA 适体固定在化学修饰的玻璃表面上。测试的细胞包括表达高水平野生型 EGFR 的原代人 GBM 细胞,以及在 Ink4a/Arf 缺陷型星形胶质细胞中过度表达最常见 EGFR 突变体(缺失外显子 2-7 的 EGFRvIII)的基因工程鼠神经胶质瘤细胞。我们发现,用抗 EGFR 适体功能化的表面可以高灵敏度和特异性地捕获人和鼠 GBM 细胞。我们的研究结果表明,新型适体底物如何可用于确定手术切除边缘是否无肿瘤细胞,或者更广泛地用于检测外周血中循环的肿瘤细胞,以提高早期检测和/或治疗后监测残留疾病的能力。